Novo Nordisk A/S’ (NYSE:NVO) executives allegedly ignored internal warnings that the company was unprepared to launch its ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

Bagsværd, Denmark, 16 May 2025 – Novo Nordisk today announced changes to its executive leadership and Board of Directors. As per mutual agreement with the Novo Nordisk Board, Lars Fruergaard ...

The Danish drugmaker has limited starter doses of Wegovy, which was approved in the US in 2021 for chronic weight management, as it struggles to meet demand, and CEO Lars Fruergaard Jorgensen said ...

Lars Fruergaard Jorgensen had led Denmark’s Novo since 2017. Ritzau Scanpix/AFP via Getty Images. He told Reuters that discussions to replace Jorgensen had taken place over the past few weeks.

Lars Fruergaard’s surprise departure from Novo Nordisk is not sitting particularly well with analysts. Lukas Leu, a portfolio manager at Bellevue Asset Management, for example, ...

Lars Fruergaard Jørgensen, CEO of Novo Nordisk, to step down as company seeks a turnaround. Company found success with Wegovy and Ozempic, but share price has fallen by half in past year.

Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to support a smooth transition to new leadership.

Lars Fruergaard Jorgensen at the Choose France Summit on May 15. Photo by LUDOVIC MARIN/POOL/AFP via Getty Images. Ozempic, which is used to treat Type 2 diabetes, was approved for use by the U.S ...

June 6 (Reuters) - Novo Nordisk's (NOVOb.CO) popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases ...

(Reuters) -Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema ...